Paper Details

  1. Home
  2. Paper Details

Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.

Author: BarloccoDaniela, PojaniEftiola

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

HDAC inhibitors, including Romidepsin, Belinostat, Vorinostat, Panobinostat, and Chidamide, are approved by the FDA for cancer treatment due to their ability to modulate histone modification and affect tumor development.
Paper Details　
Original Abstract of the Article :
Human HDACs represent a group of enzymes able to modify histone and non-histone proteins, which interact with DNA to generate chromatin. The correlation between irregular covalent modification of histones and tumor development has been proved over the last decades. Therefore, HDAC inhibitors are con...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/0929867327666200203113926

データ提供：米国国立医学図書館（NLM）

Unlocking the Power of Histone Deacetylase Inhibitors in Cancer Therapy

Histone deacetylase inhibitors (HDACi) are emerging as a promising class of drugs in cancer treatment. This research focuses on romidepsin (FK228), a potent HDACi, and its potential role in cancer chemotherapy. The study delves into the mechanism of action of romidepsin, its therapeutic applications, and its potential as a novel anticancer agent. The research highlights the importance of understanding the complex interplay between histone acetylation and cancer development and the potential of HDACi in targeting these pathways for therapeutic benefit.

Romidepsin: A New Frontier in Cancer Treatment

Romidepsin, a histone deacetylase inhibitor, has shown promising results in treating various cancers. This drug works by modulating the acetylation of histones, which are proteins that play a crucial role in regulating gene expression. By altering histone acetylation, romidepsin can effectively inhibit tumor growth and induce cancer cell death. This mechanism of action offers a novel therapeutic strategy for targeting cancer cells and potentially improving patient outcomes.

The Promise of Histone Deacetylase Inhibitors: A New Era in Cancer Therapy

The discovery of romidepsin and other HDACi has opened new avenues for cancer treatment. This class of drugs offers a targeted approach to cancer therapy, disrupting the delicate balance of gene expression within cancer cells and ultimately leading to their demise. Further research is needed to explore the full potential of HDACi in various cancer types and to develop personalized treatment strategies for individual patients.

Dr.Camel's Conclusion

Romidepsin, a powerful histone deacetylase inhibitor, holds promise for treating cancer. It's like finding a hidden oasis in the desert - a new and effective weapon in the fight against cancer. This research opens up exciting possibilities for developing new and more effective cancer therapies.

Date :
  1. Date Completed 2021-05-04
  2. Date Revised 2021-05-04
Further Info :

Pubmed ID

32013816

DOI: Digital Object Identifier

10.2174/0929867327666200203113926

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.